1. No category

Transparency Market
Research
Human Papillomavirus and Cytomegalovirus
Therapeutics Market - Global Industry Analysis,
Pipeline Analysis, Size, Share, Growth, Trends and
Forecast, 2014 – 2020
Published Date
2015-01-14
117 Page Report
Buy Now
Request Sample
Press Release
Human Papillomavirus and Cytomegalovirus Therapeutics Market
Expected to Reach USD 2.34 Billion and 0.92 Billion Globally in
2020
Transparency Market Research
State Tower,
90, State Street, Suite 700.
Albany, NY 12207
United States
www.transparencymarketresearch.com
[email protected]
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
REPORT DESCRIPTION
Human Papillomavirus and Cytomegalovirus Therapeutics Market - Global
Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast,
2014 – 2020
Human papillomavirus (HPV) and Cytomegalovirus (CMV) therapeutics market report studies
current as well as future prospects of the market on a global scale. The global market for HPV
therapeutics is segmented by drug class and applications. Various drug classes applied against
HPV infections are immunomodulators, keratolytic agents, anti-neoplastic agents, and
sinecatechins. The HPV therapeutics market is studied by application segments which include
genital warts, genital cancers, epidermodysplasia verriformis, oral papillomas, and others
(oropharyngeal cancer, laryngeal papillomatosis and others). The global HPV therapeutics market
has been extensively analyzed on the basis of the effectiveness and sales revenue of major drug
classes as well as geographic prevalence of various HPV infections.
The global CMV therapeutics market is segmented by drugs and applications. The major drugs
prescribed for the treatment of CMV infections are ganciclovir, valganciclovir, foscarnet, and
cidofovir. The CMV therapeutics treatment is applied against various CMV infections causing
retinitis, pneumonia, gastrointestinal ulcers, encephalitis and others (mouth ulcers, pharyngitis
and others).
Browse the full Human Papillomavirus and Cytomegalovirus Therapeutics
Market Report at :
http://www.transparencymarketresearch.com/hpv-cmv-therapeuticsmarket.html
Transparency Market Research
2
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
Geographically, the HPV and CMV therapeutics market has been categorized into five regions
namely, North America, Europe, South America, Asia Pacific, and Rest of the World (ROW). The
market size and forecast in terms of USD million for each of these segments has been provided
for the period 2012 to 2020, considering 2012 and 2013 as base years. The HPV and CMV
therapeutics market report also provides compounded annual growth rate (CAGR %) for each
market segment for the forecast period 2014 to 2020.
The report also provides pipeline analysis for HPV and CMV therapeutics market, which includes
sales forecast for drug candidates currently under phase III clinical trials, and also mentions other
candidates in phase I and phase II trials. The research study explains the competitive scenario in
the HPV and CMV therapeutics market through Porter’s Five Forces Analysis. A detailed analysis
of various macro as well as micro economic factors driving as well as restraining the growth of
this market, in addition to future opportunities, is provided in the market overview section of the
report. The report also provides market attractiveness analysis and value chain analysis of the
global HPV and CMV therapeutics market. Market share analysis for both HPV and CMV
therapeutics market has been included. Furthermore, pricing analysis of therapeutic drugs and
costs associated with treatment is also studied in the global HPV and CMV therapeutics market
report.
Browse the full Human Papillomavirus and Cytomegalovirus Therapeutics
Market press release at :
http://www.transparencymarketresearch.com/pressrelease/hpv-cmvtherapeutics-market.htm
A list of recommendations has been provided to help players establish a strong presence in the
market and increase their share. The report also profiles major players in the HPV and CMV
therapeutics market on the basis of various attributes such as company overview, financial
overview, product portfolio, business strategies and recent developments. Mergers, acquisitions,
regulatory approvals and other events have been explained in the company profiles section. Key
Transparency Market Research
3
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
players profiled in the report include AbbVie, Inc., Actavis plc, Clinigen Group plc, Merck & Co.,
Inc., Perrigo Company plc, Roche Holdings AG and Valeant Pharmaceuticals International, Inc.
Get Free Sample Report Human Papillomavirus and Cytomegalovirus
Therapeutics Market :
http://www.transparencymarketresearch.com/sample/sample.php?
flag=s&rep_id=3986
The research methodology was based on primary as well as secondary research. Interviews and
discussions with a wide range of key industry participants and opinion leaders revealed the real
time market scenario. This primary research represented the bulk of our research efforts, which
was further supplemented by extensive secondary research. A bottom-up approach was adopted
to arrive at global market shares for 2012 and 2013; while an impact based analysis model was
adopted to forecast revenue for each market segment. A review of key players’ product
literature, annual reports, and press releases supported the market forecast analysis. The 117
pages global HPV and CMV therapeutics market report describes various market dynamics in 51
figures and charts and 16 tables.
TABLE OF CONTENT
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
1.4 Assumptions
Transparency Market Research
4
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
1.5 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot: Global HPV Therapeutics Market
2.2 Market Snapshot: Global CMV Therapeutics Market
2.3 Global HPV and CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Chapter 3 Global HPV and CMV Therapeutics Market Overview
3.1 Market Definition and Overview
3.2 Market Dynamics
3.2.1 Human Papillomavirus (HPV) Therapeutics Market
3.2.1.1 Drivers
3.2.1.1.1 Increasing prevalence of HPV infections in developing and underdeveloped
economies is aiding the market growth
3.2.1.1.2 Global Age-specific incidence of cervical cancer
3.2.1.1.3 Severe side-effects of HPV vaccines are restraining the market growth and
creating opportunity for therapeutics market
3.2.1.2 Restraints
3.2.1.2.1 Increasing demand for minimally invasive surgical procedures in genital warts
treatment
Transparency Market Research
5
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
3.2.1.2.2 Lack of awareness in developing areas is declining the diagnostic rates
3.2.1.2.2.1 Annual number of new cases (in thousands) of cervical cancer by age
group in developed and developing regions (estimations for 2012)
3.2.1.3 Opportunities
3.2.1.3.1 Opportunity for biologics and drugs with low toxicity and short treatment regime
against HPV infections
3.2.1.3.2 Health issues raised against approved vaccines have provided wide range of
opportunities for effective and safe vaccines and therapeutics
3.2.2 Cytomegalovirus Therapeutics Market
3.2.2.1 Drivers
3.2.2.1.1 High seroprevalence adding to patient pool for CMV therapeutics market
3.2.2.1.2 High global demand for low-cost generic drugs, especially in low- and middleincome countries in South Latin America and Asia Pacific
3.2.2.2 Restraints
3.2.2.2.1 Decreasing CMV prevalence due to highly actively antiretroviral therapy (HAART)
and decreasing transplant procedures
3.2.2.3 Opportunities
3.2.2.3.1 Less competition in pediatric CMV therapeutics and increasing demand for CMV
vaccine
3.3 Value Chain Analysis
3.4 HPV Vaccines : Current Global Scenario
3.5 HPV Drug Treatment Regime Analysis: Length of HPV Drug treatment (No. of days)
Transparency Market Research
6
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
3.6 HPV Surgery Treatment: Type of Surgery and Average Cost (USD)
3.7 Pricing Analysis
3.7.1 Pricing Analysis: HPV Therapeutics Market
3.7.2 Pricing Analysis: CMV Therapeutics Market
3.7.3 HPV Treatment Cost Analysis
3.7.4 CMV Treatment Cost Analysis
3.8 Porter’s Five Forces Analysis: Global HPV & CMV Therapeutics Market
3.8.1 Bargaining Power of Suppliers
3.8.2 Bargaining Power of Buyers
3.8.3 Threat of Substitutes
3.8.4 Threat of New Entrants
3.8.5 Competitive Rivalry
3.9 Market Attractiveness Analysis, by Geography, 2013
3.9.1 HPV Therapeutics Market Attractiveness Analysis, Geography, 2013
3.9.2 CMV Therapeutics Market Attractiveness Analysis, by Geography, 2013
3.10 Market Share Analysis, by Key Players, 2013 (Value %)
3.10.1 HPV Therapeutics Market Share Analysis, by Key Players, 2013 (Value %)
3.10.2 CMV Therapeutics Market Share Analysis, by Key Players, 2013 (Value %)
Transparency Market Research
7
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
Chapter 4 Global HPV Therapeutics Market
4.1 Overview
4.2 HPV Therapeutics Market, by Drug Class
4.2.1 Overview
4.2.1.1 Global HPV Therapeutics Market Revenue, by Major Drug Classes, 2012 - 2020 (USD
Million)
4.2.2 Immunomodulators
4.2.2.1 Global Immunomodulators Market Revenue, 2012 – 2020 (USD Million)
4.2.3 Keratolytic Agents
4.2.3.1 Global Keratolytic Agents Market Revenue, 2012 – 2020 (USD Million)
4.2.4 Anti-neoplastic Agents
4.2.4.1 Global Anti-neoplastic Agents Market Revenue, 2012 – 2020 (USD Million)
4.2.5 Sinecatechins
4.2.5.1 Global Sinecatechins Market Revenue, 2012 – 2020 (USD Million)
4.3 HPV Therapeutics Market, by Application
4.3.1 Overview
4.3.1.1 Global HPV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)
4.3.2 Genital Warts
4.3.2.1 Global Genital Warts HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
4.3.3 Genital Cancer
Transparency Market Research
8
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
4.3.3.1 Global Genital Cancer HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
4.3.4 Epidermodysplasia Verruciformis
4.3.4.1 Global Epidermodysplasia Verruciformis HPV Therapeutics Market Revenue, 2012 - 2020
(USD Million)
4.3.5 Oral Papillomas
4.3.5.1 Global Oral Papillomas HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
4.3.6 Others (Oropharyngeal cancer, laryngeal papillomatosis and others)
4.3.6.1 Global Other (Oropharyngeal Cancer, Laryngeal Papillomatosis and Others) HPV
Therapeutics Market Revenue, 2012 - 2020 (USD Million)
4.4 HPV Therapeutics Market, Pipeline Analysis
4.4.1 HPV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates
4.4.2 HPV Therapeutics: Late Stage (Phase III) Drug Candidates
Chapter 5 Global Cytomegalovirus Therapeutics Market
5.1 Introduction
5.1.1 Global CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
5.2 CMV Therapeutics Market, by Major Antiviral Drugs
5.2.1 Overview
5.2.1.1 Global CMV Therapeutics Market Revenue, by Drugs, 2012 - 2020 (USD Million)
5.2.2 Ganciclovir/Valganciclovir
Transparency Market Research
9
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
5.2.2.1 Global Ganciclovir/Valganciclovir Market Revenue, 2012 - 2020 (USD Million)
5.2.3 Foscarnet
5.2.3.1 Global Foscarnet Market Revenue, 2012 - 2020 (USD Million)
5.2.4 Cidofovir
5.2.4.1 Global Cidofovir Market Revenue, 2012 - 2020 (USD Million)
5.3 CMV Therapeutics Market, by Applications
5.3.1 Overview
5.3.1.1 Global CMV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)
5.3.2 CMV Retinitis
5.3.2.1 Global CMV Retinitis Therapeutics Market Revenue,2012 - 2020 (USD Million)
5.3.3 Pneumonia
5.3.3.1 Global CMV Pneumonia Therapeutics Market Revenue, 2012 - 2020 (USD Million)
5.3.4 Gastrointestinal ulcers
5.3.4.1 Global CMV Gastrointestinal Ulcers Therapeutics Market Revenue, 2012 - 2020 (USD
Million)
5.3.5 Encephalitis
5.3.5.1 Global CMV Encephalitis Therapeutics Market Revenue, 2012 - 2020 (USD Million)
5.3.6 Others (Mouth ulcers, pharyngitis)
5.3.6.1 Global Other (Mouth ulcers, Pharyngitis)CMV Therapeutics Market Revenue,2012 - 2020
(USD Million)
Transparency Market Research
10
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
5.4 CMV Therapeutics Market, Pipeline Analysis
5.4.1 CMV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates
5.4.2 CMV Therapeutics: Late Stage (Phase III) Drug Candidates
5.4.2.1 Introduction
5.4.2.1.1 MK8228/ letermovir/AIC246
5.4.2.1.1.1 Global Letermovir Market Revenue, 2018 - 2020 (USD Million)
5.4.2.1.2 Brincidofovir/CMX001
5.4.2.1.2.1 Global Brincidofovir Market Revenue, 2016 - 2020 (USD Million)
Chapter 6 Global HPV and CMV Therapeutics Market, by Geography
6.1 Overview
6.1.1 Global HPV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
6.1.1.1 Global CMV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
6.2 North America
6.2.1 North America HPV Therapeutics Market
6.2.1.1 North America HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
6.2.2 North America CMV Therapeutics Market
6.2.2.1 North America CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
6.3 Europe
Transparency Market Research
11
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
6.3.1 Europe HPV Therapeutics Market
6.3.1.1 Europe HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
6.3.2 Europe CMV Therapeutics Market
6.3.2.1 Europe CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific HPV Therapeutics Market
6.4.1.1 Asia Pacific HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
6.4.2 Asia Pacific CMV Therapeutics Market
6.4.2.1 Asia Pacific CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
6.5 South America
6.5.1 South America HPV Therapeutics Market
6.5.1.1 South America HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
6.5.2 South America CMV Therapeutics Market
6.5.2.1 South America CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
6.6 Rest of the World
6.6.1 Rest of the World HPV Therapeutics Market
6.6.1.1 Rest of the World HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
6.6.2 Rest of the World CMV Therapeutics Market
6.6.2.1 Rest of the World CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
Transparency Market Research
12
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
Chapter 7 Recommendations
7.1.1 Market avails wide scope for new molecules as most of the first line drugs have been off patented
7.1.2 Building stronger market hold in Africa
Chapter 8 Company Profiles
8.1 AbbVie, Inc.
8.1.1 Company Overview
8.1.2 Financial Overview
8.1.3 Product Portfolio
8.1.4 Business Strategies
8.1.4.1 Strategic Collaborations and Agreements
8.1.5 Mergers and Acquisitions
8.1.6 Recent Developments
8.2 Actavis plc
8.2.1 Company Overview
8.2.2 Financial Overview
8.2.3 Product Portfolio
8.2.4 Business Strategies
Transparency Market Research
13
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
8.2.4.1 Mergers and acquisitions
8.2.4.2 Extensive R&D practices
8.2.4.3 Strategic collaborations
8.2.5 Recent Developments
8.3 Clinigen Group plc
8.3.1 Company Overview
8.3.2 Financial Overview
8.3.3 Product Portfolio
8.3.4 Business Strategies
8.3.4.1 Mergers and Acquisitions
8.3.5 Recent Developments
8.4 Merck & Co., Inc.
8.4.1 Company Overview
8.4.2 Financial Overview
8.4.3 Product Portfolio
8.4.4 Business Strategies
8.4.4.1 Mergers and acquisitions
8.4.4.2 Strategic collaborations
8.4.4.3 Expansion in emerging markets
Transparency Market Research
14
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
8.4.5 Recent Developments
8.5 Perrigo Company plc
8.5.1 Company Overview
8.5.2 Financial Overview
8.5.3 Product Portfolio
8.5.4 Business Strategies
8.5.5 Mergers and Acquisitions
8.5.6 Recent Developments
8.6 Roche Holdings AG
8.6.1 Company Overview
8.6.2 Financial Overview
8.6.3 Product Portfolio
8.6.4 Business Strategies
8.6.4.1 Consistent product launches
8.6.4.2 Mergers and Acquisitions
8.6.5 Recent Developments
8.7 Valeant Pharmaceuticals International, Inc.
8.7.1 Company Overview
8.7.2 Financial Overview
Transparency Market Research
15
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
8.7.3 Product Portfolio
8.7.4 Business Strategies
8.7.4.1 Mergers and acquisitions
8.7.5 Recent Developments
List of Figures
FIG. 1 HPV Therapeutics: Market Segmentation
FIG. 2 CMV Therapeutics: Market Segmentation
FIG. 3 Global HPV and CMV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 4 Global Age-specific incidence of cervical cancer
FIG. 5 Annual number of new cases (in thousands) of cervical cancer by age group in developed and
developing regions and five continents (estimations for 2012)
FIG. 6 Heat Map Analysis: Immunization Array of Currently Marketed Vaccines by Major Countries
FIG. 7 Global Human Immunodeficiency Virus (HIV) Prevalence, 1990 - 2008
FIG. 8 U.S. Transplant Procedures, 2000 - 2013
FIG. 9 Global HPV and CMV Therapeutics Market, Value Chain Analysis
FIG. 10 Porter’s Five Forces Analysis for the Global HPV & CMV Therapeutics Market
FIG. 11 HPV Therapeutics Market Attractiveness Analysis: by Geography, 2013
FIG. 12 CMV Therapeutics Market Attractiveness Analysis, by Geography, 2013
FIG. 13 HPV Therapeutics Market Share Analysis: by Key Players, 2013 (Value %)
Transparency Market Research
16
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
FIG. 14 CMV Therapeutics Market Attractiveness Analysis: by Key Players, 2013 (Value %)
FIG. 15 Global Immunomodulators Market Revenue, 2012 – 2020 (USD Million)
FIG. 16 Global Keratolytic Agents Market Revenue, 2012 – 2020 (USD Million)
FIG. 17 Global Anti-neoplastic Agents Market Revenue, 2012 – 2020 (USD Million)
FIG. 18 Global Sinecatechins Market Revenue, 2012 – 2020 (USD Million)
FIG. 19 Global Genital Warts HPV Therapeutics Market Revenue, 2012 – 2020 (USD Million)
FIG. 20 Global Genital Cancer HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 21 Global Epidermodysplasia Verruciformis HPV Therapeutics Market Revenue, 2012 - 2020 (USD
Million)
FIG. 22 Global Oral Papillomas HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 23 Global Other (Oropharyngeal Cancer, Laryngeal Papillomatosis and Others) HPV Therapeutics
Market Revenue, 2012 - 2020 (USD Million)
FIG. 24 Global Ganciclovir/Valganciclovir Market Revenue, 2012 - 2020 (USD Million)
FIG. 25 Global Foscarnet Market Revenue, 2012 - 2020 (USD Million)
FIG. 26 Global Cidofovir Market Revenue, 2012 - 2020 (USD Million)
FIG. 27 Global CMV Retinitis Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 28 Global CMV Pneumonia Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 29 Global CMV Gastrointestinal Ulcers Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 30 Global CMV Encephalitis Therapeutics Market Revenue, 2012 - 2020 (USD Million)
Transparency Market Research
17
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
FIG. 31 Global Other (Mouth ulcers, Pharyngitis) CMV Therapeutics Market Revenue, 2012 - 2020 (USD
Million)
FIG. 32 Global Letermovir Market Revenue, 2018 - 2020 (USD Million)
FIG. 33 Global Brincidofovir Market Revenue, 2016 - 2020 (USD Million)
FIG. 34 North America HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 35 North America CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 36 Europe HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 37 Europe CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 38 Asia Pacific HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 39 Asia Pacific CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 40 South America HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 41 South America CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 42 Rest of the World HPV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 43 Rest of the World CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
FIG. 44 Tuberculosis Cases in Africa, 1996 – 2010 (‘000)
FIG. 45 AbbVie, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 46 Actavis Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 47 Clinigen Group plc: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 48 Merck & Co., Inc.: Annual Revenue, 2011 – 2013 (USD Million)
FIG. 49 Perrigo Company plc: Annual Revenue: 2011 – 2013 (USD Million)
Transparency Market Research
18
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
FIG. 50 Roche Holdings AG: Annual Revenue: 2011 – 2013 (USD Million)
FIG. 51 Valeant Pharmaceuticals International, Inc.: Annual Revenue, 2011 – 2013 (USD Million)
List of Tables
TABLE 1 Market Snapshot: Global HPV Therapeutics Market
TABLE 2 Market Snapshot: Global CMV Therapeutics Market
TABLE 3 HPV Vaccines Sales Track
TABLE 4 Pricing Analysis: HPV Therapeutics Market
TABLE 5 Pricing Analysis: CMV Therapeutics Market
TABLE 6 HPV Strains and Diseases
TABLE 7 Global HPV Therapeutics Market Revenue, by Major Drug Classes, 2012 - 2020 (USD Million)
TABLE 8 Global HPV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)
TABLE 9 HPV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates
TABLE 10 Global CMV Therapeutics Market Revenue, 2012 - 2020 (USD Million)
TABLE 11 Global CMV Therapeutics Market Revenue, by Drugs, 2012 - 2020 (USD Million)
TABLE 12 Global CMV Therapeutics Market Revenue, by Applications, 2012 - 2020 (USD Million)
TABLE 13 CMV Therapeutics: Early Stage (Phase I and Phase II) Drug Candidates
TABLE 14 Global HPV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
TABLE 15 Global CMV Therapeutics Market Revenue, by Geography, 2012 - 2020 (USD Million)
Transparency Market Research
19
Human Papillomavirus and
Cytomegalovirus Therapeutics
Market
Browse All Pharmaceutical Market Research Reports @
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About Us
Transparency Market Research is a market intelligence company providing global business information
reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers.
We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use
proprietary data sources and various tools and techniques to gather, and analyze information. Our
business offerings represent the latest and the most reliable information indispensable for businesses to
sustain a competitive edge.
Contact
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/
Browse The Market Research Blog :
http://researchandreports.wordpress.com/ http://www.transparencymarketresearch.com
Transparency Market Research
20